Syndax Pharmaceuticals Debt to Equity

Syndax Pharmaceuticals (SNDX) currently reports a debt-to-equity ratio of 39.03. That is above the Healthcare sector average of 0.27. Use the charts on this page to explore Syndax Pharmaceuticals's debt-to-equity ratio history and peer comparisons.

Syndax Pharmaceuticals's debt-to-equity ratio of 39.03 is higher than the Healthcare sector average of 0.27. That is roughly 14600.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Syndax Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 39.03, SNDX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of 39.03, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.27. From there, open related valuation or income-statement pages for Syndax Pharmaceuticals, and consider following SNDX for alerts when major investors trade the stock.

Syndax Pharmaceuticals is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows 39.03 versus a sector average near 0.27. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SNDX with unrelated industries.